Cited by 1,635Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesFerroptosis and cancer prognosis

The DOI matches its Crossref record; 70 of the 76 references it cites were found in a registry or an index.

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Open access

Gibney, Geoffrey T, Weiner, Louis M, Atkins, Michael B·2016·The Lancet Oncology

DOI 10.1016/s1470-2045(16)30406-5PMC PMC5702534

Open this paper in CoChat — free account

Abstract

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30406-5

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Show all 76 references

Sorted by citations

Items 301–400 of 1,002

Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier, T., Fernández, E., Labidi‐Galy, S. I., Dietrich, P., Rodríguez-Bravo, V., Baciarello, G., Fizazi, K. S., & Patrikidou, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102204 · Cited by 57
Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Suryawanshi, Y. R., & Schulze, A. J. (2021) · Viruses · doi:10.3390/v13071294 · Cited by 59
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma
Chen, Y., Wang, Z., Jin, Y., Zhao, Q., Liu, Z., Zuo, Z., Ju, H., Cui, C., Yao, J., Zhang, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.016 · Cited by 58
Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics
Zhong, F., Lin, Y., Zhao, L., Yang, C., Ye, Y., & Shen, Z. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02292-0 · Cited by 58
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
Cabel, L., Loir, E., Gravis, G., Lavaud, P., Massard, C., Albiges, L. K., Baciarello, G., Loriot, Y., & Fizazi, K. S. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0232-7 · Cited by 57
Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS
Wang, J., Yi, Y., Xiao, Y., Lin, D., Liang, L., Teng, L., Ying, J. M., Lu, T., Liu, Y., Guan, Y., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0212-1 · Cited by 56
Characterization and Comparison of GITR Expression in Solid Tumors
Vence, L. M., Bucktrout, S. L., Curbelo, I. F., Blando, J. M., Smith, B. M., Mahne, A. E., Lin, J. C.-Y., Park, T., Pascua, E., Sai, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0289 · Cited by 56
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
Lu, C., Dong, X., Zhao, J., Zhang, X., Chen, H., Zhou, Q. H., Tu, H., Ai, X., Chen, X., An, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00866-6 · Cited by 56
Basis for Immunotherapy for Treatment of Meningiomas
Garzón-Muvdi, T., Bailey, D. D., Pernik, M. N., & Pan, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00945 · Cited by 56
Immune-related biomarkers in triple-negative breast cancer
Zhang, J., Tian, Q., Zhang, M., Wang, H., Wu, L., & Yang, J. (2021) · Breast Cancer · doi:10.1007/s12282-021-01247-8 · Cited by 54
Advances in Engineering Cells for Cancer Immunotherapy
Xu, X., Li, T., Shen, S., Wang, J., Abdou, P., Gu, Z., & Mo, R. (2019) · Theranostics · doi:10.7150/thno.38583 · Cited by 53
Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients
Wang, Z., Wang, C., Lin, S., & Yu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.725292 · Cited by 57
Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle
Starzer, A. M., Preusser, M., & Berghoff, A. S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221096219 · Cited by 58
STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC
Li, A., Wang, Y., Yu, Z., Tan, Z., He, L., Fu, S., Shi, M., Du, W., Luo, L., Li, Z., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.020 · Cited by 57
Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein‐1‐H3K4me3‐mediated immune escape in oesophageal squamous cell carcinoma
Liu, J., Zhou, W., Luo, X., Chen, Y., Wong, C., Liu, Z., Zheng, J., Mo, H., Chen, J.-Q., Li, J., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1410 · Cited by 55
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
Wagner, L. M., & Adams, V. R. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s124008 · Cited by 57
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
Capalbo, C., Scafetta, G., Filetti, M., Marchetti, P., & Bartolazzi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071607 · Cited by 55
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
Clouthier, D., Lien, S. C., Yang, S. Y. C., Nguyen, L. T., Manem, V. S., Gray, D., Ryczko, M. C., Razak, A. R. A., Lewin, J. H., Lheureux, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0541-0 · Cited by 55
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 53
Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab
Giannicola, R., D’Arrigo, G., Botta, C., Agostino, R. M., Medico, P. D., Falzea, A. C., Barbieri, V., Staropoli, N., Giudice, T. D., Pastina, P., et al. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1859 · Cited by 53
Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis
Deng, H., Chen, Z.-J., Qiu, X., Zhu, D., Tang, X., & Zhou, Q. (2021) · Nutrition · doi:10.1016/j.nut.2021.111345 · Cited by 53
Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma
Nishida, N. (2021) · Cancers · doi:10.3390/cancers13153666 · Cited by 56
A subset of patients with MSS/MSI‑low‑colorectal cancer showed increased CD8(+) TILs together with up‑regulated IFN‑γ
Kikuchi, T., Mimura, K., Okayama, H., Nakayama, Y., Saito, K., Yamada, L., Endo, E., Sakamoto, W., Fujita, S., Endo, H., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10953 · Cited by 55
A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses
Li, J., Qiao, H., Wu, F., Sun, S., Feng, C., Li, C., Yan, W., Lv, W., Wu, H., Liu, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.998140 · Cited by 56
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
Karam, J. A., Msaouel, P., Haymaker, C., Matin, S. F., Campbell, M. T., Zurita, A. J., Shah, A. Y., Wistuba, I. I., Marmonti, E., Duose, D. Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38342-7 · Cited by 52
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Lee, E. S., Shin, J. M., Son, S., Ko, H., Um, W., Song, S. H., Lee, J. A., & Park, J. H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801320 · Cited by 53
Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients
Ahn, J., Song, E., Oh, H., Song, D. E., Kim, W. G., Kim, T. Y., Kim, W. B., Shong, Y. K., & Jeon, M. J. (2019) · Thyroid · doi:10.1089/thy.2018.0684 · Cited by 53
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
Claps, M., Mennitto, A., Guadalupi, V., Sepe, P., Stellato, M., Zattarin, E., Gillessen, S., Sternberg, C. N., Berruti, A., de Braud, F., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102057 · Cited by 53
A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions
Kobayashi, Y., Kushihara, Y., Saito, N., Yamaguchi, S., & Kakimi, K. (2020) · Cancer Science · doi:10.1111/cas.14621 · Cited by 48
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Ngo, C., & Postel-Vinay, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030650 · Cited by 54
Eosinophils in the Tumor Microenvironment
Mattei, F., Andreone, S., Marone, G., Gambardella, A. R., Loffredo, S., Varricchi, G., & Schiavoni, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_1 · Cited by 53
Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function
Zhao, X., Wei, Y., Chu, Y., Li, Y., Hsu, J.-M., Jiang, Z., Liu, C., Hsu, J. L., Chang, W., Yang, R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2300 · Cited by 55
Current Status in Rechallenge of Immunotherapy
Hu, H. H., Wang, K., Jia, R., Zeng, Z., Zhu, M., Deng, Y., Xiong, Z., Tang, J., Xie, H., Wang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82776 · Cited by 52
Immune checkpoint inhibitors in small cell lung cancer
Pakkala, S., & Owonikoko, T. K. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.51 · Cited by 50
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma
Guo, L., Li, X., Liu, R., Chen, Y., Ren, C., & Du, S. (2020) · Cancer Medicine · doi:10.1002/cam4.3324 · Cited by 50
Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
de Lima, V. A. B., Hansen, M., Spanggaard, I., Rohrberg, K. S., Hadrup, S. R., Lassen, U., & Svane, I. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.558248 · Cited by 51
Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET
Zhou, M., Wang, X., Chen, B., Xiang, S., Rao, W., Zhang, Z., Liu, H., Fang, J., Yin, X., Deng, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05876-9 · Cited by 50
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients
Juliá, E. P., Mandó, P., Rizzo, M., Cueto, G. R., Tsou, F., Luca, R., Pupareli, C. S., Bravo, A., Astorino, W., Mordoh, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02391-z · Cited by 50
Deliver anti-PD-L1 into brain by p-hydroxybenzoic acid to enhance immunotherapeutic effect for glioblastoma
Guo, H., Wang, R., Wang, D., Wang, S., Zhou, J., Chai, Z., Yao, S., Li, J., Lu, L., Liu, Y., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.005 · Cited by 54
Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer
Cho, Y., Choi, M. G., Kim, D. H., Choi, Y. J., Kim, S. Y., Sung, K. J., Lee, J. C., Kim, S., Rho, J. K., & Choi, C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00712-2 · Cited by 50
The application of artificial intelligence and radiomics in lung cancer
Zhou, Y., Xu, X., Song, L., Wang, C., Guo, J., Zhang, Y., & Li, W. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa028 · Cited by 50
Current Trends in Cancer Immunotherapy
Filin, I. Y., Solovyeva, V. V., Kitaeva, K. V., Rutland, C. S., & Rizvanov, A. A. (2020) · Biomedicines · doi:10.3390/biomedicines8120621 · Cited by 50
Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.
Wang, S., Shi, H., Liu, T., Li, M., Zhou, S., Qiu, X., Wang, Z., Hu, W.-Y., Guo, W., Chen, X.-Q., et al. (2019) · Hepatobiliary surgery and nutrition · doi:10.21037/hbsn.2019.09.17 · Cited by 42
Recent advances in photothermal and RNA interfering synergistic therapy
Li, K., Lu, M., Xia, X., & Huang, Y. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.09.010 · Cited by 48
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
Mao, Y., Xie, H., Lv, M., Yang, Q., Shuang, Z., Gao, F., Li, S., Zhu, L., & Wang, W. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03441-3 · Cited by 55
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Placke, J., Kimmig, M., Griewank, K., Herbst, R. A., Terheyden, P. A. M., Utikal, J. S., Pföhler, C., Ulrich, J., Kreuter, A., Mohr, P., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104774 · Cited by 49
Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response
Yusuf, M. B., Amsbaugh, M. J., Burton, E., Chesney, J. A., & Woo, S. Y. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.01.101 · Cited by 50
Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer
Chae, Y. K., de Viveiros, P. A. H., Junior, G. L. L., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.016 · Cited by 48
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
Lamb, L. S., Sim, H., & McCormack, A. I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576027 · Cited by 48
Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment
Liu, Y., Geng, Y., Yue, B., Lo, P., Huang, J., & Jin, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.832942 · Cited by 50
Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy
Zhang, H., Zhao, W., Li, X., & He, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s315998 · Cited by 49
Checkpoint inhibitors as treatment for malignant gliomas: “A long way to the top”
Simonelli, M., Persico, P., Perrino, M., Zucali, P. A., Navarria, P., Pessina, F., Scorsetti, M., Bello, L., & Santoro, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.016 · Cited by 46
Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
Mocan, T., Sparchez, Z. A., Crăciun, R., Bora, N., & Leucuta, D. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1975-4 · Cited by 49
Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
Choi, J. W., Withers, S. S., Chang, H., Spanier, J. A., Trinidad, V. L. D. L., Panesar, H. K., Fife, B. T., Sciammas, R., Sparger, E. E., Moore, P. F., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235518 · Cited by 53
Cancer evolution: A means by which tumors evade treatment
Zhu, X. M., Shi, L., Xu, B., & Luo, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111016 · Cited by 51
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial
Huang, X., He, M., Peng, H., Tong, C., Liu, Z., Zhang, X., Shao, Y. W., Zhu, D., Zhang, J., Yin, J. C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002223 · Cited by 48
Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma
Kato, T., Kiyotani, K., Tomiyama, E., Koh, Y., Matsushita, M., Hayashi, Y., Nakano, K., Ishizuya, Y., Wang, C., Hatano, K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1862948 · Cited by 47
XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer
Principe, D. R., Xiong, R., Li, Y., Pham, T. D., Kamath, S. D., Dubrovskyi, O., Ratia, K. M., Huang, F., Zhao, J., Shen, Z., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116764119 · Cited by 47
Immunotherapy in triple-negative breast cancer: A literature review and new advances
Valencia, G., Rioja, P., Morante, Z., Ruiz, R., Fuentes, H. A., Castañeda, C. A., Vidaurre, T., Neciosup, S. P., & Gómez, H. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i3.219 · Cited by 48
In situ tumour arrays reveal early environmental control of cancer immunity
Ortiz-Muñoz, G., Brown, M. K., Carbone, C. B., Pechuan-Jorge, X., Rouilly, V., Lindberg, H., Ritter, A. T., Raghupathi, G., Sun, Q., Nicotra, T., et al. (2023) · Nature · doi:10.1038/s41586-023-06132-2 · Cited by 52
Atezolizumab for the treatment of non-small cell lung cancer
Santini, F. C., & Rudin, C. M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1356717 · Cited by 47
Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients
Kim, H., Kwon, H. J., Han, Y. B., Park, S. Y., Kim, E. S., Kim, S. H., Kim, Y. J., Lee, J. S., & Chung, J.-H. (2018) · Modern Pathology · doi:10.1038/s41379-018-0142-3 · Cited by 45
Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 47
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer
Karayama, M., Inui, N., Inoue, Y., Yoshimura, K., Mori, K., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02979-4 · Cited by 47
Profiling of immune features to predict immunotherapy efficacy
Ye, Y., Zhang, Y., Yang, N., Gao, Q., Ding, X., Kuang, X., Bao, R., Zhang, Z., Sun, C., Zhou, B., et al. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100194 · Cited by 46
Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy
Zhu, Y., Yan, C., Wang, X., Xu, Z., Lv, J., Xu, X., Yu, W., Zhou, M., & Yue, L. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.2011643 · Cited by 46
Immune Therapy for Liver Cancers
Hilmi, M., Vienot, A., Rousseau, B., & Neuzillet, C. (2019) · Cancers · doi:10.3390/cancers12010077 · Cited by 46
Immune contexture analysis in immuno‐oncology: applications and challenges of multiplex fluorescent immunohistochemistry
Shakya, R., Nguyen, T. H., Waterhouse, N. J., & Khanna, R. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1183 · Cited by 46
Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
Zhu, Y., Elsheikha, H. M., Wang, J.-H., Fang, S., He, J.-J., Zhu, X.-Q., & Chen, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002970 · Cited by 47
Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD‐L1 expression and enhancing T‐lymphocyte tumor‐killing activity
Sun, T., Li, M. Y., Zhang, Z. H., Wang, J. Y., Xing, Y., Ri, M., Jin, C. H., Xu, G. H., Piao, L. X., Jin, H. L., et al. (2021) · Phytotherapy Research · doi:10.1002/ptr.7103 · Cited by 45
Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
Paidi, S. K., Troncoso, J. R., Raj, P., Diaz, P. M., Ivers, J. D., Lee, D. E., Avaritt, N. L., Gies, A. J., Quick, C. M., Byrum, S. D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1438 · Cited by 46
Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics
Louie, A. D., Huntington, K. E., Carlsen, L., Zhou, L., & El‐Deiry, W. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.747194 · Cited by 46
How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC
Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 46
Deciphering lung adenocarcinoma evolution: Integrative s ingle‐cell genomics identifies the prognostic lung progression associated signature
Zhang, P., Yang, Z., Zuo, L., Zhang, G., Zhang, L., Zhang, Z., & Fan, J. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18408 · Cited by 46
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
Klümper, N., Ralser, D. J., Zarbl, R., Schlack, K., Schrader, A. J., Rehlinghaus, M., Hoffmann, M. J., Niegisch, G., Uhlig, A., Trojan, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002949 · Cited by 45
A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
Iwase, T., Blenman, K., Li, X., Reisenbichler, E., Seitz, R. S., Hout, D. R., Nielsen, T. J., Schweitzer, B. L., Bailey, D. B., Shen, Y., et al. (2021) · Cancers · doi:10.3390/cancers13194839 · Cited by 45
Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 47
Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study
Basler, L., Andratschke, N. H., Ehrbar, S., Gückenberger, M., & Tanadini‐Lang, S. (2018) · Radiation Oncology · doi:10.1186/s13014-018-0952-y · Cited by 44
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment
Sakata, Y., Kawamura, K., Ichikado, K., Shingu, N., Yasuda, Y. U., Eguchi, Y., Anan, K., Hisanaga, J., Nitawaki, T., Iio, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.011 · Cited by 44
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
Tan, Q., Wang, D., Yang, J., Xing, P., Yang, S., Li, Y., Qin, Y., He, X., Liu, Y., Zhou, S., et al. (2020) · Theranostics · doi:10.7150/thno.45816 · Cited by 44
Metal–Organic Framework-Enhanced ELISA Platform for Ultrasensitive Detection of PD-L1
Zhand, S., Razmjou, A., Azadi, S., Bazaz, S. R., Shrestha, J., Jahromi, M. A. F., & Warkiani, M. E. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00227 · Cited by 44
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
Hoffmann, F., Zarbl, R., Niebel, D., Sirokay, J. D., Fröhlich, A., Posch, C., Holderried, T. A. W., Brossart, P., Saavedra, G., Kuster, P., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00883-9 · Cited by 45
Cancer stem cells and macrophages: molecular connections and future perspectives against cancer
Aramini, B., Masciale, V., Grisendi, G., Banchelli, F., D’Amico, R., Maiorana, A., Morandi, U., Dominici, M., & Haider, K. H. (2021) · Oncotarget · doi:10.18632/oncotarget.27870 · Cited by 46
Advances in Combining Radiation and Immunotherapy in Breast Cancer
Nguyen, A. T., Shiao, S. L., & McArthur, H. L. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.03.007 · Cited by 46
GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models
Torphy, R. J., Sun, Y., Lin, R., Caffrey-Carr, A. K., Fujiwara, Y., Ho, F., Miller, E. N., McCarter, M. D., Lyons, T. R., Schulick, R. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27658-x · Cited by 44
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 43
Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
Heydt, C., Rehker, J., Pappesch, R., Buhl, T., Ball, M., Siebolts, U., Haak, A., Lohneis, P., Büttner, R., Hillmer, A. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68394-4 · Cited by 44
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
Harel, M., Lahav, C., Jacob, E., Dahan, N., Sela, I., Elon, Y., Raveh, S., Yahalom, G., Kamer, I., Zer, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004582 · Cited by 43
The potential role of m6A modifications on immune cells and immunotherapy
Gan, L., Zhao, Y., Fu, Y., & Chen, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114343 · Cited by 40
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma
Queirolo, P., & Spagnolo, F. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9660-6 · Cited by 45
Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?
Yamashita, K., Iwatsuki, M., Harada, K., Koga, Y., Kiyozumi, Y., Eto, K., Hiyoshi, Y., Ishimoto, T., Iwagami, S., Baba, Y., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0515-5 · Cited by 43
Multi‐omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma
Zhang, C., Shen, L., Qi, F., Wang, J., & Luo, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29279 · Cited by 43
Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization
Humphries, M. P., Bingham, V., Sidi, F. A., Craig, S. G., McQuaid, S., James, J. A., & Salto‐Tellez, M. (2020) · Cancers · doi:10.3390/cancers12051114 · Cited by 43
Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade
Lee, B. R., Chae, S., Moon, J., Kim, M. J., Lee, H., Ko, H. W., Cho, B. C., Shim, H. S., Hwang, D., Kim, H. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.128633 · Cited by 44
The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial
Li, R., Liu, Y., Yin, R., Yin, L., Li, K., Sun, C., Zhou, Z., Li, P., Tong, R., Xue, J., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.03.003 · Cited by 48
Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis
Chen, H., Wang, D., Zhong, Q., Tao, Y., Zhou, Y. L., & Shi, Y. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02680-y · Cited by 40
Emerging Biomaterials Imaging Antitumor Immune Response
Ma, X., Zhang, M., Wang, J., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202204034 · Cited by 42
Radiogenomic System for Non-Invasive Identification of Multiple Actionable Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer Based on CT Images
Shao, J., Ma, J., Zhang, S., Li, J., Dai, H., Liang, S., Yu, Y., Li, W., & Wang, C. (2022) · Cancers · doi:10.3390/cancers14194823 · Cited by 43

Authors: Gibney, G. T., Weiner, L. M., & Atkins, M. B.
Affiliations: Georgetown University Medical Center (US)
Corresponding author: Gibney, Geoffrey T
ORCID: Gibney, Geoffrey T
Weiner, Louis M
Atkins, Michael B
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2016-12
Volume: 17
Issue: 12
Pages: e542-e551
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(16)30406-5
PMC: PMC5702534
OpenAlex: W2559382297
Cited by: 1,635
References: 76
Citations by year: 2026: 62 · 2025: 111 · 2024: 161 · 2023: 222 · 2022: 238 · 2021: 229 · 2020: 248 · 2019: 171 · 2018: 109 · 2017: 83
FWCI: 11.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA050633, P30CA051008)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: predictive biomarkers, immune checkpoint inhibitors, PD-1, PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutational burden, immune-related gene signature, multiplex immunohistochemistry, immune-related adverse events, patient selection, melanoma
MeSH terms: Humans, Immunohistochemistry, Immunotherapy, Neoplasms, Biomarkers, Lymphocytes, Tumor-Infiltrating, Tumor Microenvironment, Cell Cycle Checkpoints, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks